Abstract：Objective To study the roles of type II 11β-hydroxysteroid dehydrogenase（11β-HSD2) and it's signaling factors in the lung tissue in pathogenesis of persistent pulmonary hypertension（PPH) in neonatal rats.Methods Six Sprague-Dawley rats on the 19th day of pregnancy were randomly divided into PPH and control groups（n=3 each). The PPH group was intraperitoneally injected with indomethacin（0.5 mg/kg) twice daily and exposed in 12% oxygen for three days, in order to prepare a fetal rat model of PPH. The control group was intraperitoneally injected with an equal volume of normal saline and exposed to air. Neonatal rats were born by caesarean section from both groups on the 22nd day of pregnancy. In each group, 15 neonatal rats were randomly selected and sacrificed. 11β-HSD2 expression in the lung tissue of neonatal rats were observed by Confocal laser technology, and serum cortisol levels and prostacyclin, renin, angiotensin and aldosterone in the lung tissue of both groups were measured using ELISA. Results 11β-HSD2 protein was widely expressed in the lung tissue of the control and PPH groups. The levels of 11β-HSD2 and prostacyclin in the lung tissue were lower in the PPH group than in the control group, while serum cortisol levels and renin, angiotensin and aldosterone in the lung tissue were higher in the PPH group than in the control group（PConclusion 11β-HSD2 and it's signaling factors play roles in pathogenesis of PPH in neonatal rats.
WANG Yan-Mei,WU Jian-Rong,TIAN Song-Bai et al. Roles of type II 11β-hydroxysteroid dehydrogenase and its signaling factors in pathogenesis of persistent pulmonary hypertension in neonatal rats[J]. CJCP, 2014, 16(9): 939-943.
Xu XF, Gu WZ, Wu XL, et al.Fetal pulmonary vascular remodeling in a rat model induced by hypoxia and indomethacin[J].J Matern Fetal Neonatal Med, 2011, 24(1):172-182.
[3]
Das R, Balonan L, Ballard HJ, et al.Chronic hypoxia inhibits the antihypertensive effect of melatonin on pulmonary artery[J].Int J Cardiol, 2008, 126(3): 340-345.
Dy J, Guan H, Sampath-Kumar R, et al.Placental 11beta-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth restriction:evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery[J].Placenta, 2008,29(2): 193-200.
[7]
Ostreicher I, Almeida JR, Campean V, et al.Changes in 11beta-hydroxysteroid dehydrogenase type 2 expression in a low-protein rat model of intrauterine growth restriction[J].Nephrol Dial Transplant, 2010, 25(10): 3195-3203.
[8]
Garbrecht MR, Schmidt TJ, Krozowski ZS, et al.11Beta-hydroxysteroid dehydrogenase type 2 and the regulation of surfactant protein A by dexamethasone metabolites[J].Am J Physiol Endocrinol Metab, 2006, 290(4): E653-E660.
Campino C, Carvajal CA, Cornejo J, et al.11β-hydroxysteroid dehydrogenase type-2 and type-1（11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension[J].Endocrine, 2010, 37(1): 106-114.
[11]
Ong SLH, Whitworth JA.How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress,and eicosanoids[J].Endocrinol Metab Clin North Am, 2011,40(2): 393-407.
[12]
Dodt C, Wellhoner JP, Schutt M, et al.Glucocorticoids and hypertension[J].Internist（Berl), 2009, 50(1): 36-41.
[13]
Hadoke PWF, Christy C, Kotelevtsev YV, et al.Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11β-hydroxysteroid dehydrogenase[J].Circulation, 2001,104(23): 2832-2837.
[14]
Hache M, Denault AY, Belisle S, et al.Inhaled prostacyclin（PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit[J].Can J Anesth, 2001, 48(9): 924-929.
[15]
Schütte H, Schell A, Schäfer C, et al.Subthreshold doses of nebulized prostacyclin and rolipram synergistaically protect against lung ischemia-reperfusion[J].Transplantation, 2003,75(6): 814-821.
[16]
Tissot C, Beghetti M.Review of inhaled iloprost for the control of pulmonary artery hypertension in children[J].Vasc Health Risk Manag, 2009, 5(1): 325-331.
